Virological and Immunological Antiretroviral Treatment Failure and Predictors Among HIV Positive Adult and Adolescent Clients in Southeast Ethiopia

Background Antiretroviral therapy (ART) regimen failure is linked to an increased risk of disease progression and death, while early detection of ART failure can help to prevent the development of resistance. This study aimed to evaluate virological and immunological ART failure and predictors among HIV-positive adult and adolescent clients in southeast Ethiopia. Methods A retrospective cohort study was implemented from January 2016 to November 30, 2020; all HIV-positive nave patients on follow-up during the study period from four hospitals were included. Virological and immunological treatment failure was the primary outcome of the study. Cox proportional hazards regression models were employed for analysis. Hazard ratios with 95% confidence intervals were reported and variables with p-values <0.05 were considered statistically significant predictors of treatment failure. Results A total of 641 HIV patients’ charts were reviewed, 62.6% of the study participants were females. Of the total study participants, 18.4% and 15% developed virological and immunological ART regimen treatment failure respectively. The median time to virological failure was 40 months. WHO stage IV [AHR = 4.616; 95% CI: (2.136–9.974)], WHO stage III [AHR = 2.323; 95% CI: (1.317–4.098)], poor adherence to HAART regimen [AHR = 3.097; 95% CI: (1.349–7.108)], and fair adherence [AHR = 2.058; 95% CI: (1.234–3.432)] were significantly associated with virological treatment failure among adolescent and adult study participants in southeast Ethiopia. Conclusion The prevalence of virological treatment failure was 18.4% (95% CI: 15.4 −21.4) and the prevalence of immunological treatment failure was 15% (95% CI: 11.8–18.4). WHO clinical stage III/IV and non-adherence were independent predictors of virological ART treatment failure. Early management of clinical WHO stages and improving patients’ ART regimen adherence are important to decrease the prevalence of ART regimen treatment failure.

[1]  M. Melku,et al.  Antiretroviral Treatment Failure and Associated Factors Among HIV-Infected Children on Antiretroviral Therapy: A Retrospective Study , 2021, HIV/AIDS.

[2]  B. D. Workneh,et al.  Prevalence and Predictors of Virological Failure Among Adults Living with HIV in South Wollo Zone, Northeast Ethiopia: A Retrospective Cohort Study , 2020, HIV/AIDS.

[3]  Setegn Eshetie,et al.  Antiretroviral treatment failure and associated factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia , 2020, AIDS Research and Therapy.

[4]  E. Negussie,et al.  Financial burden of HIV and TB among patients in Ethiopia: a cross-sectional survey , 2020, BMJ Open.

[5]  A. Misganaw,et al.  Progress towards the 2020 Fast Track HIV/AIDS reduction targets in Ethiopia comparing with neighboring countries and across ages; using Global Burden of Diseases 2017 data , 2020 .

[6]  S. W. Asgedom,et al.  Immunologic and Clinical Failure of Antiretroviral Therapy in People Living with Human Immunodeficiency Virus within Two Years of Treatment , 2020, BioMed research international.

[7]  Fitsum Weldegebreal,et al.  Magnitude of antiretroviral treatment failure and associated factors among adult HIV-positive patients in Harar public hospitals, Eastern Ethiopia , 2020, SAGE open medicine.

[8]  D. Demsie,et al.  Antiretroviral treatment failure among HIV-positive adults taking first-line therapy and associated risk factors at Adigrat General hospital, Adigart, Ethiopia 2019: A cross sectional study , 2020 .

[9]  Tadesse Tolossa,et al.  Determinants of first line antiretroviral therapy treatment failure among adult patients on ART at central Ethiopia: un-matched case control study , 2019, BMC Infectious Diseases.

[10]  Muluneh Alene,et al.  Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis , 2019, Global Health Research and Policy.

[11]  Yadeta Dessie Bacha,et al.  Clinical and immunological failure among HIV-positive adults taking first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia , 2019, BMC Public Health.

[12]  Habtemu Jarso,et al.  Predictors of virological treatment failure among adult HIV patients on first-line antiretroviral therapy in Woldia and Dessie hospitals, Northeast Ethiopia: a case-control study , 2019, BMC Infectious Diseases.

[13]  S. Hebo,et al.  Predictors of Time to First Line Antiretroviral Treatment Failure among Adult Patients Living with HIV in Public Health Facilities of Arba Minch Town, Southern Ethiopia , 2019, Ethiopian journal of health sciences.

[14]  B. Tessema,et al.  Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia , 2018, BMC Immunology.

[15]  H. Gesesew,et al.  Immunological failure in HIV-infected adults from 2003 to 2015 in Southwest Ethiopia: a retrospective cohort study , 2018, BMJ Open.

[16]  Araya Gebreyesus Wasihun,et al.  Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia , 2018, PloS one.

[17]  David P. Wilson,et al.  The Effect of Monitoring Viral Load and Tracing Patients Lost to Follow-up on the Course of the HIV Epidemic in Malawi: A Mathematical Model , 2018, Open forum infectious diseases.

[18]  R. Wanyenze,et al.  Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.

[19]  D. Haile,et al.  Predictors of Treatment Failure among Adult Antiretroviral Treatment (ART) Clients in Bale Zone Hospitals, South Eastern Ethiopia , 2016, PloS one.

[20]  M. Ayalew,et al.  First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia , 2016, HIV/AIDS.

[21]  R. Gross,et al.  Brief Report: Apparent Antiretroviral Overadherence by Pill Count is Associated With HIV Treatment Failure in Adolescents , 2016, Journal of acquired immune deficiency syndromes.

[22]  A. King,et al.  Predictors of antiretroviral therapy failure in an urban HIV/AIDS clinic in Addis Ababa, Ethiopia , 2016 .

[23]  N. Kumarasamy,et al.  Virological efficacy with first‐line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression , 2015, Tropical medicine & international health : TM & IH.

[24]  A. Tefera,et al.  Detection of immunological treatment failure among HIV infected patients in Ethiopia: a retrospective cohort study , 2015, BMC Immunology.

[25]  A. Kumie,et al.  Assessment of the magnitude and associated factors of immunological failure among adult and adolescent HIV-infected patients in St. Luke and Tulubolo Hospital, Oromia Region, Ethiopia , 2015, The Pan African medical journal.

[26]  M. Coker,et al.  Long-term outcomes of antiretroviral therapy in an adult HIV program: a 10-year retrospective cohort study in Kano, Nigeria , 2015 .

[27]  K. Yirdaw,et al.  Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia , 2015, PloS one.

[28]  Ning Wang,et al.  Outcomes of antiretroviral treatment in HIV-infected adults: a dynamic and observational cohort study in Shenzhen, China, 2003–2014 , 2015, BMJ Open.

[29]  D. Mmbando,et al.  Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data , 2015, Tropical medicine & international health : TM & IH.

[30]  S. Buchbinder,et al.  HIV infection , 2015, Nature Reviews Disease Primers.

[31]  David P. Wilson,et al.  Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces , 2014, Sexually Transmitted Infections.

[32]  G. Rutherford,et al.  Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure , 2014, AIDS.

[33]  N. Taveira,et al.  Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique , 2013, PloS one.

[34]  J. Willig,et al.  [Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru]. , 2013, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.

[35]  M. Arnedo,et al.  Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a HIV/AIDS Treatment Cohort in Busia, Kenya , 2012, PloS one.

[36]  Beth Chaplin,et al.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Desta Kassa Misgena.  The pattern of immunologic and virologic responses to Highly Active Antiretroviral Treatment (HAART): does success bring further challenges? , 2011 .

[38]  C. Gilks,et al.  The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. , 2009, American journal of clinical pathology.

[39]  Julio S. G. Montaner,et al.  A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. , 2006, The Journal of infectious diseases.

[40]  M. Chesney,et al.  Adherence to HIV combination therapy. , 2000, Social science & medicine.